Drug therapies for postmenopausal urinary incontinence by Bardsley, A.
  
Drug therapies for postmenopausal 
urinary incontinence 
 
Bardsley, A. 
 
Postprint deposited in Curve January 2016 
 
Original citation:  
Bardsley, A. (2015) Drug therapies for postmenopausal urinary incontinence. Nurse 
Prescribing, volume 13 (2). DOI: 10.12968/npre.2015.13.2.80 
 
http://dx.doi.org/10.12968/npre.2015.13.2.80 
 
Mark Allen Healthcare 
 
Copyright © and Moral Rights are retained by the author(s) and/ or other copyright 
owners. A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge. This item cannot be reproduced or quoted extensively 
from without first obtaining permission in writing from the copyright holder(s). The 
content must not be changed in any way or sold commercially in any format or medium 
without the formal permission of the copyright holders. 
 
CURVE is the Institutional Repository for Coventry University 
 
http://curve.coventry.ac.uk/open  
Drug therapies for post menopause urinary incontinence 
This article provides an update on drug therapies for the treatment of urinary incontinence in post 
menopause women. The recommendations are based on the updated guidelines from the National 
Institue for Health and Care Excellence (NICE), 2013a). Where the recommendations within the 
guidelines have not changed from the 2006 version the original has been referenced.   
Urinary Incontinence (UI) is defined as “the complaint of any involuntary leakage of urine” (Abrams 
et al, 2010). As women age, the combination of physical disabilities, co-morbidities, pregnancies and 
childbirth and the physiological effects of declining oestrogen levels put post menopausal women at 
risk of urological dysfunction, which can lead to incontinence.  
UI is commonly reported by women of all ages, with a wide range of severity and nature of 
symptoms. Although not life threatening, the symptoms can have a serious impact on the physical, 
psychological and social well being of individuals. It is estimated that 9.6 million women are affected 
by bladder problems in the UK (Hunskaar et al, 2004). A review of 36 population studies from 17 
countries undertaken by the International Continence Society in 2004 found that prevalence 
estimates for UI ranged from 5% (Van Oyen and Van Oyen, 2002) to 69% (Swithinbank, et al, 1999), 
with most studies reporting rates between 25% to 45% (Abrams et al, 2010).  
Most women experience the menopause between 45 and 55 years (Lee, 2009). The average rate of 
UI amongst post-menopausal women is 23.5% (Irwin et al, 2006 and Milsom et al, 2001) with older 
women at an increased risk of pelvic floor dysfunction (Maclennan et al, 2000) and more likely to 
have mixed and urge incontinence (Diokno et al,1986, Molander et al, 1990 and Roberts et al, 1998). 
Due to the embarrassing symptoms of UI many women do not seek help (Shaw et al, 2006) Although 
dated, a study by Sadler (1996) reported that 42% of women affected by UI symptoms waited up to 
15 years before seeking help. It is therefor important that health professionals take every oportunity 
when they come into contact with women (for example at routine screeing visits) to ask about any 
bladder symptoms they may be experiencing. 
Treatment options available for UI depend on the type of symptoms and underlying pathology, and 
include conservative measures suchas pelvic floor exercises, pharmacological therapy and surgery. 
Health professionals must be able to inform patients of all the options available to them for the 
treatment and management of their condition to ensure that patients have the opportunity to make 
informed decisions (NICE, 2013a).   
Normal bladder function 
The bladder has two main functions: to store and expel urine. Remaining continent relies on a 
balance of urethral sphincter closure and detrusor sphincter muscle activity. In storage, urethral 
closure pressure should exceed the pressure from detrusor contractions. Any increases  in intra-
abdominal pressure (such as when sneezing or coughing) are transmitted to the urethra and bladder 
equally, resulting in continence. Normal voiding is achived when urethral pressure falls and bladder 
pressure rises (Getliffe and Dolman, 2007). 
Storage and voiding are controlled by the autonomic and somatic nervous systems. The detrusor 
muscle is a layer of bladder wall made of smooth muscle fibres. As the bladder stretches during 
filling, sympathetic nerves cause the detrusor to relax and the internal sphincter to contract. To 
initiate voiding the parasympathetic nervous system is triggered to contract the detrusor and relax 
and open the internal sphincter. This relaxation and opening of the internal sphincter is under 
voluntary control (see figure 1). Problems with this mechanism and the muscles can lead to 
incontinence.   
Age related changes in women 
Maintaining continence partly relies on the urethral mucosa providing a watertight seal. Muscle 
mass generally decreases in older women, with a deterioration of 5% per decade. Perucchini  (2002) 
noted a 3% per year reduction in urethral striated muscle mass in older people. The average age for 
a women to reach the menopuase is 51 years (Lee, 2009). Urogenital tissue is dependent upon 
oestrogen stimulation to mainatin normal strcuture and function. Oestrogen receptors can be found 
in the vagina, vulva, urethra and bladder neck (Blakeman et al, 2001 and Goldstein, 2010). The 
physiological effects of the menopause result in a decline in circulating oestrogen, potentially 
leading to urogynaecological dysfunction including urgency, frequency, dysuria, incontinence and 
recurrent urinary tract infections (American College of Obstetricians and Gynaecologists Women's 
Healthcare Physicians, 2004 and MacLennan, 2000). The reduction in oestrogen also increase the 
risk of atrophic vaginitis. Atrophy or inflammation of the vagina can lead to decreased strength in 
the pelvic floor muscles, as well as vaginal discomfort, burning, itching and associated dyspareunia 
(Goldstein, 2010). Urge incontinence is more common in post-menopausal women, and in particular 
those with a history of diabetes, hysterectomy and tow or more urinary tract infections in the 
previous year (Walker, GJA and Gunasekera, P, 2011). 
Arthritis is strongly associated with urge incontinence, which could be secondary to mobility 
problems ir an autoimmune interaction that creates urge type symptoms (Jackson et al, 2004). 
Several factors can have a role in age related incontinence, such as impaired mobility and cognitive 
state, as well as environmental considerations such as toilet access (McGrother et al, 1998)    
Receptors and neurotransmitters  
Many drug therapies for urinary incontinence are based on targeting the neurotransmitters required 
for voiding. Coordination of voiding involves four principle neurotransmitters: glutamate, serotonin, 
noradrenaline and acetylcholine. The parasympathetic neurons and somatic nerves use 
acetylcholine as a primary neurotransmitter, whereas, noradrenaline is used in sympathetic neurons 
(Abrams et al, 2010).  
Acethycholine acts on muscarinic and nicotinic receptors. When stimulated, the preganglionic nerves 
releases acetycholine at the ganglion, which in turn stimulates the nicotinic receptors of 
postganglionic neurons. This releases acetycholine to stimulate the muscarinc receptors of the 
target organ. The binding of acetycholine to muscarinic receptors results in the contraction of 
bladder (Abrams et al, 2010).  
Relaxation of the bladder smooth muslce is induced by the release of noradrenaline by the 
sympathetic fibres. Within the base of the baldder is a large concentration of alpha₁-adrenergic 
receptors, which, when activated by noradrenaline produce smooth muscle contraction, which 
enhances the muscle tone of the bladder neck, urethral smooth muscle, straited external urethral 
sphincter and pelvic floor muslce, thus maintinaing continence. The somatic axons in the pudendal 
nerve also release acetycholine, which activate nicotinic receptors producing a contraction of the 
external sphincter straited muscle (Abrams et al, 2010). 
Glutamate is thought to be the principle neurotransmitter within the spinal cord, activating 
acetycholine relsease which stimulates the nicotinic receptors in the striated urethral sphincter. It is 
thought that this action is enhanced by serotoninin and noradrenaline (Abrams et al, 2010). 
There are five types of muscarinic acethycholine receptor isotopes, specialised to different tissues 
and functions within the body. M2 receptors are the most common muscarinic acetycholine 
receptor type found within the detrusor. However, M3 receptors within the bladder smooth muscle 
are thought to be the most important for inducing bladder contraction. The detrusor also contains a 
small number of beta₃-adrenoreceptors, which may facilitate muscle relaxation when activated by 
noradrenaline during bladder filling (Abrams et al, 2010).    
Assessment  
Before considering treatment options a preliminary assessment i.e. history taking and physical 
examination should be undertaken to exclude the need for specialist referral and categorise the 
women’s urinary incontinence as stress incontinence (SI), mixed urinary incontinence (UI), or 
urgency UI /overactive bladder (OAB) (NICE, 2013a). Initial treatment should be started on the basis 
of this assessment, with treament directed to the predominant symptom where mixed UI is present. 
The preliminary assessment (usually undertaken in primary care) should include:  
 A bladder diary completed for a minimum of 3 days. It is good practice for these 3 days to 
cover an variations in their usuial activities such as working and leisure time.  
 A routine digital assessment of the pelvic floor, to ascertain pelvic floor muscle strength and 
contraction 
 A urine dipstick test to detect the presence of blood, glucose, protein, leucocytes and 
nitrites in the urine – treat symptomatic urinary tract infections (those presenting with 
urgency and frequency) with antibiotics and then reassess urgency and frequency symptoms 
before initiating further pharmacological treatment. 
 Measure post-void residual volume by bladder scan for women with symptoms which 
suggest voiding dysfunction or recurrent UTI. Although an in and out catheter can be used in 
the absence of a bladder scan, the scan should be used in preference to catheterisation as 
this is less invasive and a lower incidence of adverse events. 
 Symptom scoring and quality of life assessment 
 A functional assessment – including toilet access and ease of using aids 
 Bowel dysfunction – faecal incontinence or constipation 
Urinary incontinence can also be a side effect of some medications and consideration should also be 
taken of current use of cconcomitant drugs – including ACE inhibitors, diuretics, some anti-
depressants, hormone replacement therapy (HRT), anti-psychotics, cholinesterase inhibitors, 
opioids, sedating anti-histamines, sedatives and hypnotics, which disrupt the normal storing and 
passing of urine or increase the amount of urine produced (Porter and Kaplan, 2011).  
Specialist referral 
Women with UI who present with any of the following should be urgently referred (NICE, 2006) 
microscopic haematuria in women aged 50 years and older 
 visible haematuria 
 recurrent or persisting UTI associated with haematuria in women aged 40 years and older 
 suspected malignant mass arising from the urinary tract. 
Women with UI and the following symptoms should also be considered for referral to a specialist 
service (NICE 2006): 
 persisting bladder or urethral pain 
 clinically benign pelvic masses 
 associated faecal incontinence 
 suspected neurological disease 
 symptoms of voiding difficulty 
 suspected urogenital fistulae 
 previous continence surgery 
 previous pelvic cancer surgery 
 previous pelvic radiation therapy 
 women who are found to have a palpable bladder on bimanual or abdominal examination 
after voiding.  
Treatment options 
Before considering pharmacological treatments, conservative management techniques, such as 
caffeine restriction, modification of high or low fluid intake, bladder training including time delayed 
voiding, pelvic floor muscle training and the use of a bladder diary should be tried as these can 
provide relief from the symptoms of urinary incontinence. Conservative therapies have been proven 
to be effective strategies and in motivated patients can be more effective than medication (NICE, 
2013a). The updated NICE guideline (2013a) retains the recommendation that bladder and pelvic 
floor re-training should be offered to women with urgency or mixed UI for a minimum of 3 months 
as first line treatment. If following a 3 month period of first line non pharmacological treatments, 
symptoms have failed to resolve then drug therapy may be initiated, however it is important to note 
that bladder re-training and the non-pharmacological methods should continue alongside any drug 
treatment.  
Treatment and care should respect the patient’s individual needs and preferences. Professionals 
should form a partnership with patients enabling them to make informed decisions and choices. This 
also aids in improving concordance and reducing medication waste (NICE, 2009). 
  
Pharmacological options for the management of urinary incontinence 
Overactive bladder  
The term overactive bladder (OAB) relates to symptoms if urgency with or without urinary 
incontinence, but usually with frequency and nocturia (Abrams et al, 2010) When overactive bladder 
occurs with incontinence it is refered to as “overactive bladder wet”; in the absence of incontinence 
it is refered to as “overactive bladder dry” (Haylen et al, 2010). An overactive bladder is 
characterised by the involuntary contraction of the detrusor muscle during bladder filling (Abrams et 
al, 2010)  
Where conservative measures are insufficient or ineffective pharmacological treatment should be 
considered. Drugs with an antimuscarinic or anticholinergic action remain the mainstay for the 
treatment and management of overactive bladder (NICE, 2013a). Anticholinergic medications inhibit 
the binding of acetycholine on the muscarinic receptors within the detrusor. This decreases the 
bladder (detrusor) contractions without inhibiting normal voiding, thus the ability of the bladder to 
store urine is increased and the frequency and urgency symptoms are reduced. The action and 
metabolism of the different anticholinergic medications varies depending on the affinity to a 
particular muscarinic or nicotinic receptor. Anticholinergic medications are associated with common 
adverse side effects such as constipation, dry mouth, blurred vision and somnolence. More serious 
side effects include cardiac and cognitive events (Robinson and Cardozo, 2012). Older women will be 
more susceptable to central nervous system effects, which include cognitive disturbances such as 
sedation, inability ot concentrate, memory impairment and delirium. This high rate of adverse 
effects is associated with porr concordance, with a reported discontinuation rate between 43-83%, 
with over half never fulfilling the initial prescription (Sexton et al, 2011). As anticholinergic drugs 
undergo hepatic metabolism involving cytochrome P450 isoenzymes (in particular CYP3A4 and 
CYP2D6) and renal excretion, care should be taken in women with renal or hepatic impairment. 
There is also a risk of postural hypertension. Concommittant use of other medications with 
anticholinergic properties such as antihistamines, may increase the risk of side effects (Robinson and 
Cardozo, 2012). As a result of the increased adverse effect lower doses should always be considered 
in older women.   
Before commencing any OAB drug treatment, prescribers must discuss with women: 
 the likelihood of success and associated common adverse effects,  
 the frequency and route of administration,  
 that some adverse effects such as dry mouth and constipation may indicate that treatment 
is starting to have an effect,   
 that they may not see the full benefits until they have been taking the treatment for 4 
weeks.  
 Adjustment of doses or a change of drug may be necessary depending on their response 
(NICE, 2013a) 
There are a number of different anticholinergic drugs licensed for OAB treatment within the UK. 
NICE (2013a) recommends that: 
oxybutynin (immediate release, IR),  
or tolterodine (immediate release, IR),  
or darifenacin modified release (MR) (once daily preparation), 
are the first choices for women with OAB or mixed UI.  
If the first treatment for OAB or mixed UI is not effective or well-tolerated, another drug with the 
lowest acquisition cost should be offered (NICE, 2013a). Second line antimuscarinic drugs include 
fesoterodine, tropsium chloride and popiverine. 
Flavoxate, propantheline or imipramine should not be used for the treatment of UI or OAB in 
women. When prescribing for women with concomitant neurological disease prescribers should 
refer to NICE Guidance CG148 (2012) . Duloxetine should not be used in the treatment of OAB. 
Oxybutinin hydrochloride 
Oxybutynin has a mixed action as anticholinergic and direct muscle relaxant. Oxybutinin is available 
in immediate release (IR), modified release (MR) and transdermal patch formulations (Joint 
Formulary Committee, 2014). Oxybutinin is well absorbed in the gastrointestinal system and 
extensively metabolised by the cytochrome P450 system and has a high affinity for muscarinic 
receptor in the bladder (Andersson et al, 2009).   
Immediate release oxybutynin is associated with a high risk of common side effects, and as such 
should be commenced at low doses initially. Oxybutinin IR should not be offered to frail older 
women with, for example, multiple co-morbidities, functional impairment or those with dementia or 
cognitive impairment (NICE, 2013a). In this patient group Tolterodine IR is considered first line 
option. 
Although the use of modified release oxybutynin may improve tolerability this effect has not been 
proven. The recommendation that patients are prescribed 5mg daily increasing by 5mg per week up 
to maximum of 20mg daily is considerably more expensive than using immediate release oxybutynin 
and is not recommended by NICE (2013a) first line. 
Transdermal oxybutynin patches should be offered to women who are unable to tolerate oral 
medication (NICE, 2013a). But it should be noted that side effects and poor tolerance including skin 
irritation remain a possibility (Dmochowski et al, 2003). 
Tolteradine  
Tolteradine is a competitive muscarinic agonist with no selectivity for the muscarinic receptors in the 
bladder. Tolteradine is rapidly absorbed and metabolised by the cytcochrome P450 system 
(Andersson et al, 2009). It is thought to have functional selectivity for the bladder over the salivary 
glands (Stahl et al, 1995), therefore generally better tolerated than oxybutynin, due to the lower risk 
of dry mouth (Madhuvrata et al, 2012), and does not require dose titration (NICE, 2013a). However, 
although there were lower discontinuation rates in patients taking tolterodine, patients were less 
likely to be continent after 4 weeks. The use of modified release (MR) tolterodine may offer a lower 
incidence of dry mouth and may be suitable for patients who require once daily preparations. 
Tolteradine MR is not considered cost effective by NICE (2013) and therefore not recommended first 
line. 
Darifenacin 
Darifenacin is well absorbed in the gastrointestinal system and extensively metabolised by the 
cytochrome P450 system (Andersson et al, 2009). It has relative selectivity for M3 receptors. Haab, 
Stewart and Dwyer (2004), reported a good cardiac and central nervous system safety profile, with 
few cognitive side effects, making this a good choice in older women. Darifenacin can interact with 
with CYP2D6 inhibitors and CYP3A4 inhibitors (fluconazole, grapefruit juice, erythromycin) and 
others. 
Solifenacin 
Solifenacin is well absorbed in the gastrointestinal system and extensively metabolised by the 
cytochrome P450 system and has moderate selectivity for M3 over M2 receptors (Andersson et al, 
2009). Although solifenacin demonstrates greater efficacy than tolteradine, it also has a higher 
incidence of side effects in particular constipation (Chapple, 2005). Solifenacin is also associated with 
interactions with CYP3A4 inhibitors such as ketoconazole. 
Mirabegron 
Mirabegron is a ß₃-adrenoceptor agonist, which activates beta-3-adrenoceptors causing the bladder 
to relax, which helps it to fill and store urine. It has a lower place in therapy and relatively weak 
evidence due to limited comparative data with other anti-muscarinics and limited long- term efficacy 
data. NICE (2013b) recomends mirabegron as an option for treating people for whom antimuscarinic 
drugs are contra-indicated, clinically ineffective or they have experienced unacceptable side effects. 
Dosage adjustments are required with renal and hepatic impairment and concomitant treatment 
with CYP3A inhibitors (e.g. ketoconazole, itraconazole, ritonavir, clarithromycin). Other cautions in 
prescribing include Digoxin, Type 1c anti-arrythmics (flecanide, propafenone) and tricyclic anti-
depressants (imipramine, desimipramine). 
Tropsium chloride 
Tropsium chloride has no selectivity for muscarinic receptor subtypes. It is not metabolised by the 
cytochrome P450 system, and is expected to cross the blood-brain barrier only to a limited extent, 
which results in fewer negative cognitive side effects, which can make it a useful choice in older 
women (Widemann, Fusgen and Hauri, 2001). 
Fesoterodine 
Fesoterodine is metabolised in the liver and has a selective affinity to M3 receptors. Fesoterodine 
has well documented efficacy and an acceptable adverse event profile (Andersson et al, 2009). 
Propiverine Hydrochloride 
Propiverine Hydrochloride is rapidly absorbed and has a large first pass effect. It has a combined 
antimuscarinic and calcium antagonistic action (Tokuno., Chowdhury and Tomita, 1993).Propiverine 
has no selectivity for muscarinic receptor subtypesand the role of the calcium antagonistic 
component is not established (Andersson et al, 2009).  
Oestrogens 
For older women intravaginal oestrogen therapy can provide some improvement in the symptoms of 
UI especially in post-menopausal women with vaginal atrophy (Panay et al,  2013, Cody et al, 2009 
and NICE, 2013a). Intravaginal oestrogen has an effect on the bladder and urethral epithelium and 
may help relieve symptoms of urinary frequency, urgency and possibly reduce recurrent urinary 
tract infections (Panay et al,  2013)  
Systemic oestrogen or hormone replacement therapy is contraindicated in the treatment of urinary 
incontinence due to the association with systemic side effects such as thromboembolism and stroke 
and may in fact increase the likelihood of developing urinary incontinence (Panay et al,  2013 and 
NICE, 2006).  
Botulinum toxin 
First line invasive intervention for OAB is multiple injections of botulinum toxin (type A) directly into 
the bladder detrusor muscle every 6-12 months. Botulinum toxin (type A) is a neurotoxin that 
inhibits the release of acetylcholine from the presynaptic cholinergic nerve ending, which decreases 
the muscle contractibility owing to localized chemical denervation (Nitti et al; EMBARK Study Group, 
2013 and Andersson  et al, 2009). Botulinum toxin type A has been shown to reduce urinary 
symptoms of OAB by 35-50% compared with placebo   (NICE, 2013a). Botox is reserved for women 
with more severe incontinence that affects their quality of life, which has not reposnded to 
conservative tharpy including drug management. One of the main side effects is that the toxin can 
paralyse the bladder, leading to large residual urine volumes. Around 20% of patients will need to 
perform self catheterisation, therefore all women who are offered botulinum toxin injections must 
be willing and able to undertake self-catheterisation prior to the procedure (NICE, 2013a)  
Desmopressin 
 
Desmopressin is a synthetic analogue of vasopressin or antidiuretic hormone, which inhibits 
diuresis, while avoiding vasopressive effects (NICE, 2013). When given at night it reduces 
nocturnal urine production (nocturia). NICE (2013) recommend desmopressin, may be 
considered specifically to reduce nocturia in women with UI or OAB who find it a 
troublesome symptom. Particular caution should be taken when prescribing for women with 
cystic fibrosis. The prescribing of desmopressin should be avoided in women over 65 years 
with cardiovascular disease or hypertension (NICE, 2013).  
 
 Stress Urinary Incontinence (SUI) 
SUI is the “complaint of involuntary leakage on effort or exertion, or on sneezing or coughing” 
(Abrams et al, 2010). Evidence suggests that the urethra is hormonally sensative with oestrogen 
providing an advantagous effect (Blakeman, 2001). 
Treatment of (SUI) 
The mainstay of treatment for SUI remains pelvic floor exercises and lifestyle options such as weight 
loss (NICE, 2006).  
Duloxetine 
Duloxetine remains the only drug currently licensed for the treatment of SUI (Joint Formulary 
Committee, 2014). Duloxetine is a serotonin and noradrenaline reuptake inhibitor that acts mainly in 
the spinal cord to increase pudendal nerve activity, which increases urethral sphincter closure 
pressure within the storage phase (NICE, 2006). Duloxetine is associated with a high incidence of 
adverse effects which include nausea, dry mouth and constipation, as such it also has a high 
discontinuation rate (NICE, 2006). NICE (2013a) recommend Duloxetine as a second line therapy for 
women only if surgery is declined or unsuitable. 
Conclusion 
Drug therapy can play an important role in the treatment and management of urinary incontinence 
in post-menopausal women. Clinicians need to ensure when considering medication as an option 
that they include the women in a prescribing partnership, which insures that they are fully informed 
of the potential benefits and side effects. Particular care should be taken when prescribing for older 
women with concomitant conditions and medications due to the increased risk of interactions and 
side effects in this group of patients. For some patients, a trial of more than one drug may be 
required before an appropriate option is found and patients should be informed of this, to avoid 
disillusionment with their care. 
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